Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):352–356. doi: 10.1038/bjc.1993.339

Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.

L Seymour 1, W R Bezwoda 1
PMCID: PMC1968584  PMID: 8347490

Abstract

The effects of interferon-alpha (IFN) plus tamoxifen (TMX) in the treatment of advanced breast cancer were assessed. Changes of in vivo biologic determinants including hormone receptors, P24 protein, Ki-67 and growth factor expression were evaluated. Seven patients with advanced, heavily pretreated, breast cancer with accessible disease, underwent biopsy prior to and after sequential treatment with IFN and IFN plus TMX. Clinically 4/7 patients responded to treatment with one complete and three partial remissions. Apart from the favourable response rate the sequential in vivo changes in expression of tumour variables were of considerable interest. IFN treatment consistently increased the expression of the estrogen receptor (ER) and of the estrogen regulated protein P24 while decreasing the expression of the proliferation associated antigen Ki-67. Addition of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in progesterone receptor (PR) expression. When the effect of either IFN or IFN plus TMX on the expression of two growth factors was assessed they were found to be somewhat variable. While PDGF expression tended to be suppressed, there was no clinical correlation with response to therapy. TGF beta expression was found in all patients prior to treatment and while all non-responders showed reduction of TGF beta following treatment, the alterations were variable amongst responders (including two patients with increased expression, one with no change, and one with decreased expression). It is concluded that both IFN and TMX exert multiple effects on the expression of tumour biologic variables and that while the study confirmed some of the predictions from in vitro models, the in vivo effect are more complex than has been appreciated from the models. From the clinical point of view, it might be expected that treatment which enhances the expression of ER in tumours should have a positive effect on the response to TMX.

Full text

PDF
352

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. J., Hajj H., Edwards D. P., Bjercke R. J., McGuire W. L. Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies. Cancer Res. 1983 Sep;43(9):4297–4301. [PubMed] [Google Scholar]
  2. Ariad S., Seymour L., Bezwoda W. R. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat. 1991 Dec;20(1):11–17. doi: 10.1007/BF01833352. [DOI] [PubMed] [Google Scholar]
  3. Arrick B. A., Korc M., Derynck R. Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res. 1990 Jan 15;50(2):299–303. [PubMed] [Google Scholar]
  4. Barnard N. J., Hall P. A., Lemoine N. R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. doi: 10.1002/path.1711520407. [DOI] [PubMed] [Google Scholar]
  5. Bezwoda W. R., Esser J. D., Dansey R., Kessel I., Lange M. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer. 1991 Aug 15;68(4):867–872. doi: 10.1002/1097-0142(19910815)68:4<867::aid-cncr2820680432>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  6. Bezwoda W. R., Meyer K. Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res. 1990 Sep 1;50(17):5387–5391. [PubMed] [Google Scholar]
  7. Byar D. P., Sears M. E., McGuire W. L. Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer. 1979 Mar;15(3):299–310. doi: 10.1016/0014-2964(79)90041-0. [DOI] [PubMed] [Google Scholar]
  8. Ciocca D. R., Adams D. J., Edwards D. P., Bjercke R. J., McGuire W. L. Estrogen-induced 24K protein in MCF-7 breast cancer cells is localized in granules. Breast Cancer Res Treat. 1984;4(4):261–268. doi: 10.1007/BF01806037. [DOI] [PubMed] [Google Scholar]
  9. Coates A., Gebski V., Bishop J. F., Jeal P. N., Woods R. L., Snyder R., Tattersall M. H., Byrne M., Harvey V., Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987 Dec 10;317(24):1490–1495. doi: 10.1056/NEJM198712103172402. [DOI] [PubMed] [Google Scholar]
  10. Edwards D. P., Adams D. J., McGuire W. L. Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF-7). Breast Cancer Res Treat. 1981;1(3):209–223. doi: 10.1007/BF01806261. [DOI] [PubMed] [Google Scholar]
  11. Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R., Dickson R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 1987 Feb 13;48(3):417–428. doi: 10.1016/0092-8674(87)90193-0. [DOI] [PubMed] [Google Scholar]
  13. Macheledt J. E., Buzdar A. U., Hortobagyi G. N., Frye D. K., Gutterman J. U., Holmes F. A. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1991 Aug;18(3):165–170. doi: 10.1007/BF01990032. [DOI] [PubMed] [Google Scholar]
  14. Perosio P. M., Brooks J. J. Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis. Lab Invest. 1989 Feb;60(2):245–253. [PubMed] [Google Scholar]
  15. Powles T. J., Ashley S., Ford H. T., Gazet J. C., Nash A. G., Neville A. M., Coombes R. C. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet. 1984 Jun 23;1(8391):1369–1373. doi: 10.1016/s0140-6736(84)91872-5. [DOI] [PubMed] [Google Scholar]
  16. Saiki I., Murata J., Nakajima M., Tokura S., Azuma I. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res. 1990 Jun 15;50(12):3631–3637. [PubMed] [Google Scholar]
  17. Seymour L., Bezwoda W. R., Meyer K., Behr C. Detection of P24 protein in human breast cancer: influence of receptor status and oestrogen exposure. Br J Cancer. 1990 Jun;61(6):886–890. doi: 10.1038/bjc.1990.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Seymour L., Bezwoda W. R., Meyer K. Tumor factors predicting for prognosis in metastatic breast cancer. The presence of P24 predicts for response to treatment and duration of survival. Cancer. 1990 Dec 1;66(11):2390–2394. doi: 10.1002/1097-0142(19901201)66:11<2390::aid-cncr2820661124>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  19. Sica G., Natoli V., Stella C., Del Bianco S. Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer. 1987 Nov 15;60(10):2419–2423. doi: 10.1002/1097-0142(19871115)60:10<2419::aid-cncr2820601011>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  20. Solary E., Prud'homme J. F., Gauville C., Magdelenat H., Calvo F. Modulation of proliferation, estradiol receptors and estrogen regulated protein PS2/BCEI in human breast cancer cell lines by gamma interferon. J Biol Regul Homeost Agents. 1991 Jul-Sep;5(3):98–106. [PubMed] [Google Scholar]
  21. Wakefield L. M., Thompson N. L., Flanders K. C., O'Connor-McCourt M. D., Sporn M. B. Transforming growth factor-beta: multifunctional regulator of cell growth and phenotype. Ann N Y Acad Sci. 1988;551:290–298. doi: 10.1111/j.1749-6632.1988.tb22355.x. [DOI] [PubMed] [Google Scholar]
  22. Walker R. A., Camplejohn R. S. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer. 1988 Mar;57(3):281–283. doi: 10.1038/bjc.1988.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Welch D. R., Fabra A., Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7678–7682. doi: 10.1073/pnas.87.19.7678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. van den Berg H. W., Leahey W. J., Lynch M., Clarke R., Nelson J. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. Br J Cancer. 1987 Mar;55(3):255–257. doi: 10.1038/bjc.1987.49. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES